相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Polymyxin dose tunes the evolutionary dynamics of resistance in multidrug-resistant Acinetobacter baumannii
Jinxin Zhao et al.
CLINICAL MICROBIOLOGY AND INFECTION (2022)
Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria
George G. Zhanel et al.
DRUGS (2022)
Biogenic silver nanoparticle (Bio-AgNP) has an antibacterial effect against carbapenem-resistant Acinetobacter baumannii with synergism and additivity when combined with polymyxin B
Suzane Olachea Allend et al.
JOURNAL OF APPLIED MICROBIOLOGY (2022)
Molecular Mechanisms of Drug Resistance in Staphylococcus aureus
Beata Mlynarczyk-Bonikowska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Synergistic activities of colistin combined with other antimicrobial agents against colistinresistant Acinetobacter baumannii clinical isolates
Mashal M. Almutairi
PLOS ONE (2022)
Global epidemiology, genetic environment, risk factors and therapeutic prospects of mcr genes: A current and emerging update
Masego Mmatli et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2022)
Combined effect of Polymyxin B and Tigecycline to overcome Heteroresistance in Carbapenem-Resistant Klebsiella pneumoniae
Yuan Tian et al.
MICROBIOLOGY SPECTRUM (2021)
Pharmacodynamic evaluation of suppression of in vitro resistance in Acinetobacter baumannii strains using polymyxin B-based combination therapy
Nayara Helisandra Fedrigo et al.
SCIENTIFIC REPORTS (2021)
Resveratrol enhances the antimicrobial effect of polymyxin B on Klebsiella pneumoniae and Escherichia coli isolates with polymyxin B resistance
Li Liu et al.
BMC MICROBIOLOGY (2020)
Dissecting the Molecular Mechanism of Colistin Resistance in mcr-1 Bacteria
Jianguo Li et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2020)
The Characteristic of Virulence, Biofilm and Antibiotic Resistance ofKlebsiella pneumoniae
Guoying Wang et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2020)
Pharmacokinetic-pharmacodynamic modelling to investigate in vitro synergy between colistin and fusidic acid against MDR Acinetobacter baumannii
Lynette M. Phee et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Present and Future of Carbapenem-resistant Enterobacteriaceae (CRE) Infections
Beatriz Suay-Garcia et al.
ANTIBIOTICS-BASEL (2019)
Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network
Yawei Zhang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Colistin: still a lifesaver for the 21st century?
Ilias Karaiskos et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2017)
Antimicrobial Resistance of Hypervirulent Klebsiella pneumoniae: Epidemiology, Hypervirulence-Associated Determinants, and Resistance Mechanisms
Chang-Ro Lee et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2017)
Clinical Pharmacokinetics and Pharmacodynamics of Colistin
Nicolas Gregoire et al.
CLINICAL PHARMACOKINETICS (2017)
Plasmid-mediated colistin resistance: an additional antibiotic resistance menace
P. Nordmann et al.
CLINICAL MICROBIOLOGY AND INFECTION (2016)
Colistín en la era post-antibiótica
Alejandro Aguayo et al.
Revista Chilena de Infectologia (2016)
Fusidic Acid: A Bacterial Elongation Factor Inhibitor for the Oral Treatment of Acute and Chronic Staphylococcal Infections
Prabhavathi Fernandes
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
Klebsiella pneumoniae: characteristics of carbapenem resistance and virulence factors
Esra Deniz Candan et al.
ACTA BIOCHIMICA POLONICA (2015)
Population Pharmacokinetics of Fusidic Acid: Rationale for Front-Loaded Dosing Regimens Due to Autoinhibition of Clearance
Juergen B. Bulitta et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Colistin pharmacokinetics: the fog is lifting
W. Couet et al.
CLINICAL MICROBIOLOGY AND INFECTION (2012)
'Old' antibiotics for emerging multidrug-resistant bacteria
Phillip J. Bergen et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2012)
Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies
Yun Cai et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Efforts to Support the Development of Fusidic Acid in the United States
Prabhavathi Fernandes et al.
CLINICAL INFECTIOUS DISEASES (2011)
The Safety Record of Fusidic Acid in Non-US Markets: A Focus on Skin Infections
Carl N. Kraus et al.
CLINICAL INFECTIOUS DISEASES (2011)
Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing
Lauren M. Lim et al.
PHARMACOTHERAPY (2010)
Colistin in the 21st century
Roger L. Nation et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2009)
Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance:: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model
Phillip J. Bergen et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
Jian Li et al.
LANCET INFECTIOUS DISEASES (2006)
In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus
P Grohs et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
分享论文
